Table 5.
Effect of time after menopause of starting hormone replacement therapy on risk of hip fracture
| Years after menopause at time of starting treatment | No of cases/ controls | Odds ratio* (95% CI) |
|---|---|---|
| Never used | 956/2073 | 1.0 (reference) |
| All users: | ||
| ⩽2 | 61/276 | 0.53 (0.39 to 0.73) |
| 3-8 | 19/98 | 0.48 (0.28 to 0.79) |
| ⩾9 | 29/59 | 0.86 (0.52 to 1.43) |
| Current users: | ||
| ⩽2 | 16/138 | 0.29 (0.16 to 0.50) |
| 3-8 | 7/56 | 0.30 (0.13 to 0.69) |
| ⩾9 | 17/43 | 0.62 (0.33 to 1.18) |
| Current users, total use >2 years: | ||
| ⩽2 | 16/107 | 0.32 (0.18 to 0.58) |
| 3-8 | 4/33 | 0.28 (0.10 to 0.82) |
| ⩾9 | 3/14 | 0.26 (0.07 to 1.02) |
| Last use ⩽5 years: | ||
| ⩽2 | 28/181 | 0.37 (0.24 to 0.59) |
| 3-8 | 11/77 | 0.35 (0.18 to 0.69) |
| ⩾9 | 26/52 | 0.75 (0.43 to 1.32) |
| Last use⩽5 years, total use >2 years: | ||
| ⩽2 | 25/130 | 0.40 (0.24 to 0.65) |
| 3-8 | 6/40 | 0.35 (0.14 to 0.84) |
| ⩾9 | 5/17 | 0.36 (0.12 to 1.08) |
*
Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis (yes/no).